Adjuvant (Alliance A011801 Compass HER2 Residual Disease)
- Result Type
- clinical trial
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
You are viewing results from Research and Clinical Trials.
6results found for:
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Status: Active, Recruiting
To evaluate the impact of using EndoPredict clinically to inform treatment decisions for extended endocrine therapy and the subsequent impact on patient outcome
Status: Active, Recruiting
The purpose of this study is to find out how genetics, biologics and behavior might contribute to
Status: Active, Recruiting
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Status: Active, Recruiting
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active, Recruiting
TARGeted Intraoperative radioTherapy (TARGIT) Registry Database (TARGIT R)
Status: Active, Recruiting
Check-ups, screenings and sick visits for adults and children.
Expertise and advanced technologies in all areas of medicine.
For serious accidents, injuries and conditions that require immediate medical care.
After-hours, weekend and holiday services.
Convenient walk-in care clinics for your non-urgent health needs.
We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences